Skip to main content
. 2023 Apr 14;29(5):1103–1112. doi: 10.1038/s41591-023-02321-8

Extended Data Table 5.

SAEs (≥2 patients in total) suspected to be related to the study treatments

graphic file with name 41591_2023_2321_Tab5_ESM.jpg

Values are number of patients, n (%).

Preferred terms by MedDRA version 23.0 and CTCAE version 4.0.

All treated patients (primary and expansion cohorts).

No suspected SAEs in the GIST and the ASI cohorts; hence, they are not included in the table.

Includes SAEs that are related to either dabrafenib or trametinib.

aAll three cases were cutaneous.

G, grade; MedDRA, Medical Dictionary for Regulatory Activities.